Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.49 |
| ▸ | CFD | P00746 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6494445 | 0.87 | CYP4F2 (0.54) | MRGPRX4PPARAPPARGALOX5OR51E2 | |
| SCHEMBL24515574 | 0.86 | MTNR1A (0.48) | MRGPRX4PPARAPPARGALOX5OR51E2 | |
| SCHEMBL31432825 | 0.85 | ALOX5 (0.47) | PPARAALOX5OR51E2PTPN1KMT2A | |
| SCHEMBL3940302 | 0.84 | KMT2A (0.59) | ALOX5OR51E2KMT2AMEN1 | |
| SCHEMBL3686214 | 0.83 | HDAC1 (0.51) | ALOX5OR51E2KMT2AMEN1 | |
| SCHEMBL26104257 | 0.83 | MRGPRX4 (0.55) | MRGPRX4PPARAPPARGCFD | |
| SCHEMBL20522149 | 0.83 | PPARG (0.60) | MRGPRX4PPARAPPARGALOX5CFD | |
| SCHEMBL31135560 | 0.83 | MRGPRX4 (0.55) | MRGPRX4PPARAPPARGCFD | |
| SCHEMBL28287006 | 0.81 | CYP19A1 (0.65) | ALOX5OR51E2KMT2AMEN1CYP19A1 | |
| SCHEMBL9503760 | 0.81 | MAPT (0.61) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176204-B2 | Substituted carboxylic acid derivatives | KYORIN PAHRMACEUTICAL CO., LTD. (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050101521-A1 | Substituted carboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1348698-A1 | SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Kyorin Pharmaceutical Co., Ltd. (JP) | 2003-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101521-A1 | Substituted carboxylic acid derivatives | PPARG, PPARA, PPARD | MRGPRX4 2167/4885PPARA 2/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.